



S2 Fig. Kaplan-Meier plots showing overall survival (OS) of all patients with and without *TP53* mutations after immune checkpoint inhibitor (ICI) treatment initiation (A), OS of male patients with and without *TP53* mutations after ICI treatment initiation (B), OS of female patients with and without *TP53* mutations after ICI treatment initiation (C). CI, confidence interval; MT, mutated; WT, wild-type.